Aug 7, 2019 | Press Release
Exclusive distribution agreement with Daiichi Sankyo, Inc. expands rare disease and complex therapeutic specialty pharmacy needs CARY, N.C. (August 7, 2019) — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas,...
Aug 1, 2019 | Press Release
CARY, N.C., August 1, 2019—Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, was selected by Bayer HealthCare as a specialty pharmacy provider for NUBEQA® (darolutamide) for the treatment of non-metastatic...
Jul 8, 2019 | Press Release
FDA-approved drug is new treatment option for patients with relapsed or penta-refractory multiple myeloma CARY, N.C., July 8, 2019—Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been...
Mar 21, 2019 | Press Release
Exclusive distribution agreement for rare disease therapy strengthens the specialty pharmacy’s footprint beyond oncology CARY, N.C. (March 21, 2019) — Biologics by McKesson continues to expand its capabilities as a specialty pharmacy expert in oncology and complex...
Dec 7, 2018 | Press Release
XOSPATA is FDA Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation CARY, N.C., December 7, 2018 — Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas,...
Sep 26, 2018 | Press Release
COPIKTRA is a Dual Inhibitor Approved for Treatment of Adult Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Relapsed or Refractory Follicular Lymphoma CARY, N.C., September 26, 2018—Biologics by McKesson, an...
